Neurocrine Biosciences (FRA:NB3) Property, Plant and Equipment: €465 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €152.20
GF Value €165.56
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Property, Plant and Equipment?

Neurocrine Biosciences FRA:NB3 -2.56% 94 Property, Plant and Equipment is €465 Mil as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €165.56 (Fairly Valued). The stock has 6 warning signs investors should review.

Neurocrine Biosciences's quarterly net PPE declined from Sep. 2025 (€482 Mil) to Dec. 2025 (€466 Mil) and declined from Dec. 2025 (€466 Mil) to Mar. 2026 (€465 Mil).

Neurocrine Biosciences's annual net PPE increased from Dec. 2023 (€318 Mil) to Dec. 2024 (€565 Mil) but then declined from Dec. 2024 (€565 Mil) to Dec. 2025 (€466 Mil).


Neurocrine Biosciences  (FRA:NB3) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Neurocrine Biosciences Property, Plant and Equipment Related Terms


Neurocrine Biosciences Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Property, Plant and Equipment Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.88 137.45 318.47 565.36 465.60

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 545.01 506.33 482.40 465.60 465.37
FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of €465 Mil mean?
Neurocrine Biosciences (FRA:NB3) has a Property, Plant and Equipment of €465 Mil as of Mar. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Property, Plant and Equipment too high?
Neurocrine Biosciences' current Property, Plant and Equipment is €465 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Property, Plant and Equipment compare to VTRS and ELAN?
Neurocrine Biosciences' Property, Plant and Equipment of €465 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Drug Manufacturers company?
A good Property, Plant and Equipment depends on the Drug Manufacturers industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Property, Plant and Equipment is €465 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €165.56, compared to a current price of €152.20 — trading 8.1% below its estimated fair value. The current Property, Plant and Equipment is €465 Mil. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Property, Plant and Equipment is €465 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €152.20 is trading 8.1% below its estimated GF Value™ of €165.56. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for FRA:NB3:

  • Property, Plant and Equipment: €465 Mil
  • GF Value™: €165.56 vs. price of €152.20 (8.1% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€152.20
Price
€165.56
GF Value